←
Mark Dowling34 posts
Mark Dowling avatar

Mark Dowling

@markrdowling

Haematology registrar at @PeterMacCC, immunologist @WEHI_Research, ex-quantum physicist and new dad

◷ Joined July 2009
Pietro Di Ciaccio avatar
⟳ Mark Dowling retweeted
Pietro Di Ciaccio@prpdiciaccio·5 Feb 2024

Important work regarding high prevalence of BCMA expression in PBL. There is no consensus in the treatment of RR PBL and anti BCMA therapies are intriguing. Interestingly the two patients exposed to CD19 directed CART in this small series died. #lymsm

B-cell maturation antigen expression & clinical features of plasmablastic lymphoma: - 17/18 patients w BCMA expression on IHC (94%) - Median 75% of cells were BCMA+ - 61% intermed-strong BCMA staining onlinelibrary.wiley.com/doi/… #lymsm #mmsm @BritSocHaem @WileyOnc_Hem @DrAEvens

Post attachmentPost attachmentPost attachment
Dr T. Comeau , MD avatar
⟳ Mark Dowling retweeted
Dr T. Comeau , MD@SCTNB·10 Jun 2023

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations | Blood | American Society of Hematology ashpublications.org/blood/ar…

NEJM avatar
⟳ Mark Dowling retweeted
NEJM@NEJM·5 Jun 2023

Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:

Dylan O'Donnell 🦋 avatar
⟳ Mark Dowling retweeted
Dylan O'Donnell 🦋@erfmufn·16 Jan 2022

Physics Quiz! How many Hiroshimas/Megatons of explosive force does it take to get the Tennis off the front page of all major Australian news outlets? (Clue: it's more than 1000 Hiroshimas)

Graham Collins avatar
⟳ Mark Dowling retweeted
Graham Collins@graham74GC·14 Dec 2021

Bishop - Belinda - Tisa-cel v SOC in 2L Agg NHL - Refract or < 12mo 1L, bridging OK - 1 EP: EFS - death or PD/SD at 12 week assessment - 322 random, 33% SOC had ASCT - Median EFS both arms 3mo - 51% crossed to tisa-cel tisa-cel < liso/Axi - or study design issue? #ASH21 #lymsm

Post attachmentPost attachmentPost attachmentPost attachment
Doherty Institute avatar
⟳ Mark Dowling retweeted
Doherty Institute@TheDohertyInst·23 Aug 2021

Statement on the Doherty Institute modelling: The Doherty Institute understands how extremely challenging lockdown restrictions are for everyone.

Joshua Casan avatar
⟳ Mark Dowling retweeted
Joshua Casan@JoshCasan·13 Jul 2021

Thrilled to see our group’s paper out. rdcu.be/cogHo Amongst the first demonstrating the potential for CRISPR-Cas13-based targeting of live SARS-CoV-2. Special congrats to the brilliant @Farehlab. Lucky to be part of this project as my first venture into basic science.